SIRT and Immunotherapy for Advanced Liver Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination treatment: a radiation therapy called SIRT (given through a tube into the liver) plus an immunotherapy drug (atezolizumab, with or without bevacizumab). It is for people with advanced liver cancer that cannot be treated with surgery or other standard procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a type of liver cancer called hepatocellular carcinoma (HCC), confirmed by a scan or biopsy.
- Your liver tumor is larger than 6 cm.
- Your liver function is good enough (Child-Pugh score A to B7).
- Surgery, ablation, transplant, or embolization (TACE) cannot cure your cancer.
- You have cancer in the liver's main blood vessels or a high tumor marker (AFP over 100).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether combining three treatments—an immunotherapy drug (Atezo), a blood-vessel-blocking drug (Bev), and a radioactive bead treatment (SIRT-Y90)—can help patients with advanced liver cancer that cannot be surgically removed. The goal is to see if using all three together works better than using fewer treatments.
This trial tests a combination of three treatments: an immunotherapy drug (Sintilimab), a targeted therapy (Bevacizumab), and a type of internal radiation (SIRT) for people with intermediate or advanced liver cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a two-step approach for liver cancer that has spread into the portal vein. First, you receive internal radiation (SIRT) to shrink the tumor, followed by immunotherapy drugs (durvalumab with or without tremelimumab) to help your immune system fight the cancer. The goal is to see if this combination is safe and effective.
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a procedure called SIRT (radioactive beads) for people with liver cancer that can't be surgically removed. The goal is to see if this triple approach works better than standard treatments.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
Hear when a new Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.